Table 6. Vaccine type availability and factors that influence choice of vaccine type by the GP in 2019/2020, in the risk group ≥65 years, Spain.
| SPAIN | |
|---|---|
| ≥65y | |
| n (%) | |
| Vaccine types available | (N = 99) |
| 1 | 21 (21.2) |
| >1 | 78 (78.8) |
| The following factors influence choice of vaccine type by the GP a | (N = 78) |
| Patient preference | 4 (5.1) |
| Directed by vaccine availability | 55 (70.5) |
| Patient characteristics | 42 (53.8) |
| The following patient characteristics influence choice of vaccine type by the GP b | (N = 39) |
| Younger age | 5 (12.8) |
| Older age | 30 (76.9) |
| Presence of multiple comorbidities | 26 (66.7) |
| Presence of specific comorbidities | 10 (25.6) |
| Higher severity of comorbidities | 17 (43.6) |
| Frailty | 22 (56.4) |
| Other | 9 (23.1) |
aTIV: adjuvanted trivalent influenza vaccine; n: number of GPs that chose a particular answer; N: number of GPs that answered the question; QIVe: egg-based quadrivalent influenza vaccine; QIVc: cell-based quadrivalent influenza vaccine.
a This question was only posed to GPs that answered “>1 type” to the previous question.
b This question was only posed to GPs that answered “patient characteristics” to the previous question.